The Affiliated Hospital of Xuzhou Medical University — Biomedical Watch V2

Traitements7programmes

Essais4liés

Publications2liées

SourceDBlocale

Traitements

7

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
HN2302 InjectionThis is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).	Lupus, Myasthénie	Non applicable		China	À vérifier
Recombinant StreptokinaseThis is a multicenter, prospective, pragmatic, randomized controlled trial (IMPROVE-STEMI) aiming to evaluate the efficacy and safety of intracoronary low-dose recombinant streptokinase combined with primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI). A total of 3,300 patients will be enrolled, consisting of a core randomized study (300 patients, 1:1 ratio to pPCI + recombinant streptokinase vs. pPCI alone) and an extended observational study (3,000 patients receiving pPCI + recombinant streptokinase). The primary outcome measure is the coronary angiography-derived index of microcirculatory resistance (caIMR) immediately after the procedure. Secondary outcomes include the incidence of major adverse cardiovascular events (MACE) at 1 year, TIMI flow grade, corrected TIMI frame count (CTFC), and myocardial salvage index. The study duration is 24 months after the first patient enrollment, with follow-up visits scheduled at Day 5, Week 4, Week 12, Week 24, and Week 52.	Maladie coronarienne	Phase 4	À vérifier	China	À vérifier
UCAR-T cellsThis is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.	Lupus	NA	Immunomodulation + Thérapie cellulaire	China	À vérifier
UCAR-T cellsThis is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.	Lupus	NA	Thérapie cellulaire	China	À vérifier
HN2302 InjectionThis is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).	Lupus	Phase 1		China	À vérifier
HN2302 InjectionThis is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).	Myasthénie	Non applicable		China	À vérifier
Recombinant StreptokinaseThis is a multicenter, prospective, pragmatic, randomized controlled trial (IMPROVE-STEMI) aiming to evaluate the efficacy and safety of intracoronary low-dose recombinant streptokinase combined with primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI). A total of 3,300 patients will be enrolled, consisting of a core randomized study (300 patients, 1:1 ratio to pPCI + recombinant streptokinase vs. pPCI alone) and an extended observational study (3,000 patients receiving pPCI + recombinant streptokinase). The primary outcome measure is the coronary angiography-derived index of microcirculatory resistance (caIMR) immediately after the procedure. Secondary outcomes include the incidence of major adverse cardiovascular events (MACE) at 1 year, TIMI flow grade, corrected TIMI frame count (CTFC), and myocardial salvage index. The study duration is 24 months after the first patient enrollment, with follow-up visits scheduled at Day 5, Week 4, Week 12, Week 24, and Week 52.	Maladie coronarienne	Phase 4	À vérifier	China	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Recombinant Streptokinase	Maladie coronarienne	Phase 4	NCT07875179	IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI	NOT_YET_RECRUITING
HN2302 Injection	Myasthénie	Non applicable	NCT07413835	Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)	RECRUITING
HN2302 Injection	Lupus	Phase 1	NCT07523282	AID — Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases	NOT_YET_RECRUITING
UCAR-T cells	Lupus	NA	NCT07155369	UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases	ACTIVE_NOT_RECRUITING

Publications

2

Molécule	Indication / population	Titre	Journal	Date
UCAR-T cells		CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia.	Chinese medical journal
UCAR-T cells		A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.	Blood